leadf
logo-loader
viewArix Bioscience PLC
(
LSE:ARIXFRA:3HY
)

Arix portfolio firm Artios Pharma to collaborate with Novartis on cancer therapy development

The company said Artois will receive an upfront payment of US$20mln as part of the collaboration and will also be eligible to receive up to US$1.3bn in milestone payments as well as any sales royalties

Arix Bioscience PLC - Arix portfolio firm Artios Pharma to collaborate with Novartis on cancer therapy development

Arix Bioscience PLC (LON:ARIX) said its portfolio company Artios Pharma Limited, in which it owns a 12.4% stake, has agreed a global research collaboration with Swiss pharma giant Novartis to create a new generation of DNA Damage Response (DDR) cancer therapies.

Under the three-year deal, the company said Artois and Novartis will perform target discovery and validation while the latter will select up to three exclusive DDR targets and receive worldwide rights for these to be utilised with its Radioligand Therapies (RLTs).

READ: Arix Bioscience leads US$152mln funding round for Pyxis Oncology

Novartis will make an upfront payment of US$20mln to Artois and provide near term research funding to support the collaboration.

Artois will also be eligible to receive up to US$1.3bn in discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of products commercialised by Novartis.

"This collaboration will exploit Artios' innovative discovery technology to build a pipeline of RLT combination therapies that can change the current paradigm in cancer treatment. Following the recent multi-billion dollar deal with Merck, the collaboration with Novartis further strengthens Artios' leadership in the field of DDR. We are proud to continue supporting Artios as it becomes a clinical-stage precision medicine company", Arix executive chairman Naseem Amin said in a statement.

Quick facts: Arix Bioscience PLC

Follow
LSE:ARIX

Price: 164 GBX

Market Cap: £213.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Hochschild Mining reveals 'profitable' PEA on its heavy rare earths project...

Hochschild Mining Head of Investor Relations Charles Gordon joined Proactive New York to discuss the Peru-based gold and silver miner's recent developments within its heavy rare earths project, recently renamed Aclara. Gordon says the group recently revealed a preliminary economic assessment...

15 hours, 24 minutes ago

Transaction in own shares

12 hours, 41 minutes ago

Transaction in own shares

1 day, 12 hours ago

Transaction in own shares

2 days, 12 hours ago

Transaction in own shares

3 days, 12 hours ago

Transaction in own shares

4 days, 12 hours ago

Transaction in own shares

1 week, 1 day ago

Transaction in own shares

1 week, 2 days ago

Transaction in own shares

1 week, 3 days ago

2 min read